GaddumMemorialLecture 2014: receptors as an evolving concept: from switches to biased microprocessors
Author:
- 21 July 2015
- journal article
- lecture
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (17) , 4238-4253
Abstract
This review is based on the JR Vane Medal Lecture presented at the BPS Winter Meeting in December 2014 by T. Kenakin. A recording of the lecture is included assupporting informationand can also be viewed online here:https://www.youtube.com/watch?v=xrP81AQ8l‐8. Pharmacological models used to describe drug agonism and antagonism have evolved over the past 20 years from a parsimonious model describing single active and inactive receptor states to models of multiconformational receptor systems modified by ligand conformational selection. These latter models describe the observed, presently underexploited, pharmacological mechanism of ligand‐directed biased signalling. Biased signals can be quantified with transduction coefficients (ΔΔLog(τ/KA) values), a scale grounded in theBlack/Leff operational model; this enables the optimization of biased profiles through medicinal chemistry. The past decades have also brought the availability of new technologies to measure multiple functional effects mediated by seven transmembrane receptors. These have confirmed that drugs can have many efficacies, which may be collaterally linked, that is there is no linear sequence of activities required. In addition, new functional screening assays have introduced increasing numbers of allosteric ligands into drug discovery. These molecules are permissive (they do not necessarily preclude endogenous signallingin vivo); therefore, they may allow better fine tuning of pathological physiology. The permissive quality of allosteric ligands can also change the quality of endogenous signalling efficacy (‘induced bias’) as well as the quantity of signal; in this regard, indices related to ΔΔLog(τ/KA) values (namely ΔLog(αβ) values) can be used to quantify these effects for optimization in the drug discovery process. All of these added scales of drug activity will, hopefully, allow better targeting of candidate molecules towards therapies.Keywords
This publication has 67 references indexed in Scilit:
- Biased signalling and allosteric machines: new vistas and challenges for drug discoveryBritish Journal of Pharmacology, 2012
- A Simple Method for Quantifying Functional Selectivity and Agonist BiasACS Chemical Neuroscience, 2012
- Crystal structure of the β2 adrenergic receptor–Gs protein complexNature, 2011
- Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat AstrogliaMolecular Pharmacology, 2011
- Structure of a nanobody-stabilized active state of the β2 adrenoceptorNature, 2011
- Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug ScreeningMolecular Pharmacology, 2010
- Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug DiscoveryPharmacological Reviews, 2010
- A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein ActivationScience Translational Medicine, 2009
- Estimation of Relative Microscopic Affinity Constants of Agonists for the Active State of the Receptor in Functional Studies on M2 and M3 Muscarinic ReceptorsMolecular Pharmacology, 2009
- Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor SubtypesThe Journal of Pharmacology and Experimental Therapeutics, 2009